Abstract
The issue number is given in front of the pagination
Abdelnour, C., see Cañabate, P. (4) 1099–1108
Abela, M., see Van Langenhove, T. (1) 163–170
Abushakra, S., see Rafii, M.S. (2) 401–411
Adibfar, A., see Suridjan, I. (3) 885–896
Adrait, A., see Nguyen, M.-F. (1) 123–137
Adrait, A., X. Perrot, M.-F. Nguyen, M. Gueugnon, C. Petitot, L. Collet, A. Roux and M. Bonnefoy on behalf of the ADPHA study group, Do Hearing Aids Influence Behavioral and Psychological Symptoms of Dementia and Quality of Life in Hearing Impaired Alzheimer’s Disease Patients and Their Caregivers? (1) 109–121
Aguado, B., see Alonso, R. (1) 55–67
Aladinskiy, V., see Ivachtchenko, A.V. (4) 1043–1063
Albensi, B.C., see Snow, W.M. (3) 841–853
Alcolea, D., see Sala, I. (3) 909–918
Alegret, M., see Cañabate, P. (4) 1099–1108
Alexopoulos, P., see Robb, C. (1) 69–78
Alkon, D.L., see Nelson, T.J. (2) 521–535
Alonso, J.F., see Ochoa, J.F. (4) 1229–1244
Alonso, R., D. Pisa, B. Aguado and L. Carrasco, Identification of Fungal Species in Brain Tissue from Alzheimer’s Disease by Next-Generation Sequencing (1) 55–67
Ambarki, K., see Edsbagge, M. (3) 821–828
Amen, D.G., W.S. Harris, P.M. Kidd, S. Meysami and C.A. Raji, Quantitative Erythrocyte Omega-3 EPA Plus DHA Levels are Related to Higher Regional Cerebral Blood Flow on Brain SPECT (4) 1189–1199
Ames, D., see Gardener, S.L. (1) 193–201
An, H., M.-H. Cho, D.-H. Kim, S. Chung and S.-Y. Yoon, Orexin Impairs the Phagocytosis and Degradation of Amyloid-β Fibrils by Microglial Cells (1) 253–261
Anderson, J., see Garcia, A. (1) 139–145
Anderson, M.L., see Dublin, S. (2) 435–448
Andreasson, U., see Edsbagge, M. (3) 821–828
Andreazza, A., see Suridjan, I. (3) 885–896
Andrew, M.K., see Godin, J. (1) 231–242
Andrieu, S., see Bennys, K. (1) 87–97
Archer, A.E., see Morris, J.K. (4) 1129–1135
Armstrong, J.J., see Godin, J. (1) 231–242
Artero, S., see Vos, S.J.B. (2) 537–547
Ashok, A., see Tripathi, A.K. (4) 1109–1119
Asthana, A., see Tripathi, A.K. (4) 1109–1119
Asthana, S., see Dougherty, R.J. (4) 1089–1097
Baazaoui, N. and K. Iqbal, Prevention of Amyloid-β and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound (1) 215–230
Babulal, G.M., S.H. Stout, D. Head, D.M. Holtzman, A.M. Fagan, J.C. Morris and C.M. Roe, Neuropsychiatric Symptoms and Alzheimer’s Disease Biomarkers Predict Driving Decline: Brief Report (3) 675–680
Badi, H., see Lacosta, A.-M. (3) 661–667
Baena, A., see Ochoa, J.F. (4) 1229–1244
Bahado-Singh, R.O., see Yilmaz, A. (2) 355–359
Bai, F., see Sun, J. (3) 597–612
Baksi, S., see Tripathi, A.K. (4) 1109–1119
Balouch, S., see Macedo, A.C. (4) 993–1002
Banks, S.J., see Ritter, A. (3) 695–699
Barabash, A., see López-Higes, R. (4) 1201–1215
Barath, P., see Majerova, P. (2) 507–520
Barhum, Y., see Segal-Gavish, H. (2) 389–400
Barker, P.B., see Li, Y. (4) 1175–1187
Barrett-Connor, E., see Laughlin, G.A. (3) 871–883
Bartley, L., see Van Langenhove, T. (1) 163–170
Bartos, A., see Kolarova, M. (2) 471–478
Batista, K.M.P., see García, B. (1) 185–192
Beattie, B.L., see Sepehry, A.A. (2) 449–462
Ben Zimra, M., see Pinner, E. (4) 1137–1149
Bendlin, B.B., see Dougherty, R.J. (4) 1089–1097
Benke, T., see Pertl, M.-T. (4) 1077–1087
Bennys, K., A. Gabelle, C. Berr, D. De Verbizier, S. Andrieu, B. Vellas and J. Touchon, MAPT-DSA Study group, Cognitive Event-Related Potential, an Early Diagnosis Biomarker in Frail Elderly Subjects: The ERP-MAPT-PLUS Ancillary Study (1) 87–97
Benson, G., see Pasquini, L. (3) 763–773
Ben-Zur, T., see Segal-Gavish, H. (2) 389–400
Berezuk, C., K.K. Zakzanis, J. Ramirez, A.C. Ruocco, J.D. Edwards, B.L. Callahan and S.E. Black for the Alzheimer’s Disease Neuroimaging Initiative, Functional Reserve: Experience Participating in Instrumental Activities of Daily Living is Associated with Gender and Functional Independence in Mild Cognitive Impairment (2) 425–434
Bergstrom, J., see Laughlin, G.A. (3) 871–883
Berr, C., see Bennys, K. (1) 87–97
Binosha Fernando, W.M.A.D., see Gardener, S.L. (1) 193–201
Bittlinger, M., see Viaña, J.N.M. (2) 289–301
Black, S.E., see Berezuk, C. (2) 425–434
Blackburn, D., see Mirheidari, B. (2) 373–387
Blauw, G.J., see Mahinrad, S. (1) 275–283
Blennow, K., see Deters, K.D. (4) 1245–1254
Blennow, K., see Edsbagge, M. (3) 821–828
Blennow, K., see Sala-Llonch, R. (3) 829–840
Blesa, R., see Sala, I. (3) 909–918
Bloom, G.S., see Swanson, E. (3) 803–820
Boada, M., see Cañabate, P. (4) 1099–1108
Boada, M., see Nave, S. (4) 1217–1228
Bohlken, J., L. Jacob and K. Kostev, Association between Anti-Dementia Treatment Persistence and Daily Dosage of the First Prescription: A Retrospective Analysis in Neuropsychiatric Practices in Germany (1) 37–44
Bonnefoy, M., see Adrait, A. (1) 109–121
Bonnefoy, M., see Nguyen, M.-F. (1) 123–137
Boots, E.A., see Dougherty, R.J. (4) 1089–1097
Borroni, E., see Nave, S. (4) 1217–1228
Borza, T., see Sala-Llonch, R. (3) 829–840
Bourgeat, P., see Lim, Y.Y. (4) 1293–1302
Bozzali, M., see Serra, L. (1) 171–184
Brækhus, A., see Sala-Llonch, R. (3) 829–840
Breckenridge, L., see Swanson, E. (3) 803–820
Bruschini, M., see Serra, L. (1) 171–184
Bu, X.-L., see Jin, W.-S. (3) 919–925
Buist, R., see Snow, W.M. (3) 841–853
Burnham, S., see Gardener, S.L. (1) 193–201
Burns, J.M., see Morris, J.K. (4) 1129–1135
Burrell, J.R., see Van Langenhove, T. (1) 163–170
Busse, M., E. Michler, F. von Hoff, H. Dobrowolny, R. Hartig, T. Frodl and S. Busse, Alterations in the Peripheral Immune System in Dementia (4) 1303–1313
Busse, M., see Kunschmann, R. (1) 243–252
Busse, S., see Busse, M. (4) 1303–1313
Busse, S., see Kunschmann, R. (1) 243–252
Caballero-Martínez, M.C., see García, B. (1) 185–192
Cabrera, L.Y., see Vega, I.E. (4) 979–992
Cai, R., see Tian, S. (4) 1163–1173
Calderón-Garcidueñas, L. and S.M. de la Monte, Apolipoprotein E4, Gender, Body Mass Index, Inflammation, Insulin Resistance, and Air Pollution Interactions: Recipe for Alzheimer’s Disease Development in Mexico City Young Females (3) 613–630
Callahan, B.L., see Berezuk, C. (2) 425–434
Caltagirone, C., see Serra, L. (1) 171–184
Cañabate, P., G. Martínez, M. Rosende-Roca, M. Moreno, S. Preckler, S. Valero, O. Sotolongo, I. Hernández, M. Alegret, G. Ortega, A. Espinosa, A. Mauleón, L. Vargas, O. Rodríguez, C. Abdelnour, D. Sánchez, E. Martín, A. Ruiz, L. Tárraga and M. Boada, Social Representation of Dementia: An Analysis of 5,792 Consecutive Cases Evaluated in a Memory Clinic (4) 1099–1108
Cao, W.S., see Maezawa, I. (2) 559–574
Caravaggio, F., see Chung, J.K. (3) 747–762
Carey, T., see Nave, S. (4) 1217–1228
Carlsson, C.M., see Dougherty, R.J. (4) 1089–1097
Carmona-Iragui, M., see Sala, I. (3) 909–918
Carrasco, L., see Alonso, R. (1) 55–67
Carrière, I., see Vos, S.J.B. (2) 537–547
Caselli, R.J., see Williams, S.M. (1) 23–35
Cash, M.K., see Macdonald, I.R. (2) 491–505
Castañón, S., see García, B. (1) 185–192
Cercignani, M., see Serra, L. (1) 171–184
Cermakova, P., M. Nelson, J. Secnik, S. Garcia-Ptacek, K. Johnell, J. Fastbom, L. Kilander, B. Winblad, M. Eriksdotter and D. Religa, Living Alone with Alzheimer’s Disease: Data from SveDem, the Swedish Dementia Registry (4) 1265–1272
Chakravarty, M.M., see Chung, J.K. (3) 747–762
Chan, C.C.H., see Chan, S.C.C. (3) 735–746
Chan, S.C.C., C.C.H. Chan, A.Y. Derbie, I. Hui, D.G.H. Tan, M.Y.C. Pang, S.C.L. Lau and K.N.K. Fong, Chinese Calligraphy Writing for Augmenting Attentional Control and Working Memory of Older Adults at Risk of Mild Cognitive Impairment: A Randomized Controlled Trial (3) 735–746
Chan, S.S.M., see Lu, H. (3) 927–937
Chan, W., see Li, K. (2) 361–371
Chan, Y., see Malek-Ahmadi, M. (2) 575–583
Chander, R.J., see Tan, Y.J. (2) 413–423
Chen, K., see Malek-Ahmadi, M. (2) 575–583
Chen, Y., see Jin, W.-S. (3) 919–925
Cheng, J., see Li, Y. (4) 1175–1187
Chirila, F.V., see Nelson, T.J. (2) 521–535
Cho, M.-H., see An, H. (1) 253–261
Christensen, H., see Mirheidari, B. (2) 373–387
Christian, B.T., see Dougherty, R.J. (4) 1089–1097
Chui, H.C., see Liu, C.Y. (4) 1035–1041
Chung, J.K., E. Plitman, S. Nakajima, F. Caravaggio, Y. Iwata, P. Gerretsen, J. Kim, H. Takeuchi, S. Shinagawa, R. Patel, M.M. Chakravarty and A. Graff-Guerrero, for the Alzheimer’s Disease Neuroimaging Initiative, Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer’s Disease Pathology (3) 747–762
Chung, S., see An, H. (1) 253–261
Clarimón, J., see Sala, I. (3) 909–918
Clark, E.N., see Mahinrad, S. (1) 275–283
Collet, L., see Adrait, A. (1) 109–121
Collet, L., see Nguyen, M.-F. (1) 123–137
Combs, C.K., see Manocha, G.D. (3) 775–787
Comijs, H.C., see Vos, S.J.B. (2) 537–547
Cook, D.B., see Dougherty, R.J. (4) 1089–1097
Coppola, G., see Liu, C.Y. (4) 1035–1041
Costa, M., see Oliveira, J. (4) 953–978
Costafreda, S., see Sadiq, D. (2) 463–470
Counts, S.E., see Vega, I.E. (4) 979–992
Crane, P.K., see Dublin, S. (2) 435–448
Crean, S., see Harding, A. (2) 337–348
Cui, D., see Xie, B. (1) 263–274
Cui, J., see Li, Q. (2) 549–558
Czech, C., see Nave, S. (4) 1217–1228
da Cruz e Silva, O.A.B., see Oliveira, J. (4) 953–978
Dale, R., see Snow, W.M. (3) 841–853
Danino, O., see Segal-Gavish, H. (2) 389–400
Dartigues, J.-F., see Vos, S.J.B. (2) 537–547
Darvesh, S., see Macdonald, I.R. (2) 491–505
de Almeida, M.S.C., see Oliveira, J. (4) 953–978
de Craen, A.J.M., see Mahinrad, S. (1) 275–283
de Eulate, R.G., I. Goñi, A. Galiano, M. Vidorreta, M. Recio, M. Riverol, J.L. Zubieta and M.A. Fernández-Seara, Reduced Cerebral Blood Flow in Mild Cognitive Impairment Assessed Using Phase-Contrast MRI (2) 585–595
de la Monte, S.M., see Calderón-Garcidueñas, L. (3) 613–630
De Verbizier, D., see Bennys, K. (1) 87–97
de Vugt, M., see Vos, S.J.B. (2) 537–547
DeBay, D.R., see Macdonald, I.R. (2) 491–505
Deckers, K., see Vos, S.J.B. (2) 537–547
Deev, A., see Gordon, R. (3) 711–724
Delazer, M., see Pertl, M.-T. (4) 1077–1087
Delgado-Losada, M.L., see López-Higes, R. (4) 1201–1215
Delmar, P., see Nave, S. (4) 1217–1228
Del-Río, D., see López-Higes, R. (4) 1201–1215
Derbie, A.Y., see Chan, S.C.C. (3) 735–746
Desai, V., see Tripathi, A.K. (4) 1109–1119
Deters, K.D., S.L. Risacher, S. Kim, K. Nho, J.D. West, K. Blennow, H. Zetterberg, L.M. Shaw, J.Q. Trojanowski, M.W. Weiner and A.J. Saykin for the Alzheimer Disease Neuroimaging Initiative, Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer’s Disease (4) 1245–1254
Di Domenico, C., see Serra, L. (1) 171–184
Di Lucente, J., see Maezawa, I. (2) 559–574
Dobrowolny, H., see Busse, M. (4) 1303–1313
Dobson-Stone, C., see Van Langenhove, T. (1) 163–170
Doody, R.S., see Li, K. (2) 361–371
Doody, R.S., see Nave, S. (4) 1217–1228
Doran, E., see Rafii, M.S. (2) 401–411
Dougherty, R.J., S.A. Schultz, T.K. Kirby, E.A. Boots, J.M. Oh, D. Edwards, C.L. Gallagher, C.M. Carlsson, B.B. Bendlin, S. Asthana, M.A. Sager, B.P. Hermann, B.T. Christian, S.C. Johnson, D.B. Cook and O.C. Okonkwo, Moderate Physical Activity is Associated with Cerebral Glucose Metabolism in Adults at Risk for Alzheimer’s Disease (4) 1089–1097
Dublin, S., R.L. Walker, S.L. Gray, R.A. Hubbard, M.L. Anderson, O. Yu, T.J. Montine, P.K. Crane, J.A. Sonnen and E.B. Larson, Use of Analgesics (Opioids and Nonsteroidal Anti-Inflammatory Drugs) and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort (2) 435–448
Dukart, J., see Nave, S. (4) 1217–1228
Duque, J.E., see Ochoa, J.F. (4) 1229–1244
Ecay-Torres, M., see Tort-Merino, A. (3) 855–870
Edsbagge, M., U. Andreasson, K. Ambarki, C. Wikkelsø, A. Eklund, K. Blennow, H. Zetterberg and M. Tullberg, Alzheimer’s Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate (3) 821–828
Edwards, D., see Dougherty, R.J. (4) 1089–1097
Edwards, J.D., see Berezuk, C. (2) 425–434
Edwards, J.D., The Importance of Identifying Early Changes in Cardiac Structure and Function for the Prevention of Cognitive Impairment and Dementia (1) 285–288
Eklund, A., see Edsbagge, M. (3) 821–828
Eriksdotter, M., see Cermakova, P. (4) 1265–1272
Espinosa, A., see Cañabate, P. (4) 1099–1108
Estanga, A., see Tort-Merino, A. (3) 855–870
Evans, C., see Rafii, M.S. (2) 401–411
Fagan, A.M., see Babulal, G.M. (3) 675–680
Fang, C., see Li, Q. (2) 549–558
Fastbom, J., see Cermakova, P. (4) 1265–1272
Feldman, H.H., see Sepehry, A.A. (2) 449–462
Fernández-Menéndez, S., see García, B. (1) 185–192
Fernández-Seara, M.A., see de Eulate, R.G. (2) 585–595
Fernández-Vega, I., see García, B. (1) 185–192
Filipcik, P., see Skrabana, R. (4) 1017–1025
Fischer, B., see Segal-Gavish, H. (2) 389–400
Fjell, A.M., see Sala-Llonch, R. (3) 829–840
Fong, K.N.K., see Chan, S.C.C. (3) 735–746
Fontoura, P., see Nave, S. (4) 1217–1228
Fortea, J., see Sala, I. (3) 909–918
Fortea, J., see Tort-Merino, A. (3) 855–870
Fowler, C., see Lim, Y.Y. (4) 1293–1302
Foxe, D., see Van Langenhove, T. (1) 163–170
Frisoni, G.B., see Vos, S.J.B. (2) 537–547
Frodl, T., see Busse, M. (4) 1303–1313
Frodl, T., see Kunschmann, R. (1) 243–252
Frölich, L., see Wolfsgruber, S. (3) 939–950
Fung, A.W.T., see Lu, H. (3) 927–937
Gabelle, A., see Bennys, K. (1) 87–97
Gabrielli, G.B., see Serra, L. (1) 171–184
Galiano, A., see de Eulate, R.G. (2) 585–595
Gallagher, C.L., see Dougherty, R.J. (4) 1089–1097
Galluzzo, L., see Vos, S.J.B. (2) 537–547
Gao, C.-Y., see Jin, W.-S. (3) 919–925
Gao, J., see Siedlak, S.L. (4) 1027–1033
Gao, X., see Li, Y. (4) 1175–1187
Garcia, A., S. Mathur, M.C. Kalaw, E. McAvoy, J. Anderson, A. Luedke, J. Itorralba and S. Mai, Quantitative 3D Telomeric Imaging of Buccal Cells Reveals Alzheimer’s Disease-Specific Signatures (1) 139–145
García, B., C. Martín, O. García-Suárez, B. Muñiz-Alonso, H. Ordiales, S. Fernández-Menéndez, J. Santos-Juanes, L. Lorente-Gea, S. Castañón, I. Vicente-Etxenausia, K.M.P. Batista, I. Ruiz-Díaz, M.C. Caballero-Martínez, J. Merayo-Lloves, I. Guerra-Merino, L.M. Quirós and I. Fernández-Vega, Upregulated Expression of Heparanase and Heparanase 2 in the Brains of Alzheimer’s Disease (1) 185–192
Garcia-Ptacek, S., see Cermakova, P. (4) 1265–1272
García-Suárez, O., see García, B. (1) 185–192
Gardener, S.L., S.R. Rainey-Smith, H.R. Sohrabi, M. Weinborn, G. Verdile, W.M.A.D. Binosha Fernando, Y.Y. Lim, K. Harrington, S. Burnham, K. Taddei, C.L. Masters, S.L. Macaulay, C.C. Rowe, D. Ames, P. Maruff, R.N. Martins and for the AIBL Research Group, Increased Carbohydrate Intake is Associated with Poorer Performance in Verbal Memory and Attention in an APOE Genotype-Dependent Manner (1) 193–201
Geda, Y.E., see Pink, A. (4) 1273–1281
Geddes, T., see Yilmaz, A. (2) 355–359
Gerlach, I., see Nave, S. (4) 1217–1228
Gerretsen, P., see Chung, J.K. (3) 747–762
Ghatak, A., see Manocha, G.D. (3) 775–787
Giannandrea, D., see Paolacci, L. (2) 323–335
Gilaberte, I., see Nave, S. (4) 1217–1228
Gilbert, F., see Viaña, J.N.M. (2) 289–301
Gill, D.P., see Shellington, E.M. (1) 17–22
Godin, J., J.J. Armstrong, K. Rockwood and M.K. Andrew, Dynamics of Frailty and Cognition After Age 50: Why It Matters that Cognitive Decline is Mostly Seen in Old Age (1) 231–242
Goñi, I., see de Eulate, R.G. (2) 585–595
Gordon, R., I. Podolski, E. Makarova, A. Deev, E. Mugantseva, S. Khutsyan, F. Sengpiel, A. Murashev and V. Vorobyov, Intrahippocampal Pathways Involved in Learning/Memory Mechanisms are Affected by Intracerebral Infusions of Amyloid-β25-35 Peptide and Hydrated Fullerene C60 in Rats (3) 711–724
Graff-Guerrero, A., see Chung, J.K. (3) 747–762
Graham, S.F., see Yilmaz, A. (2) 355–359
Gray, S.L., see Dublin, S. (2) 435–448
Grimmer, T., see Nave, S. (4) 1217–1228
Grimmer, T., see Pasquini, L. (3) 763–773
Grönholm-Nyman, P., see Tort-Merino, A. (3) 855–870
Grothe, M.J., see Pasquini, L. (3) 763–773
Gruper, Y., see Pinner, E. (4) 1137–1149
Gu, L. and Z. Zhang, Exploring Potential Electrophysiological Biomarkers in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Event-Related Potential Studies (4) 1283–1292
Guerra-Merino, I., see García, B. (1) 185–192
Gueugnon, M., see Adrait, A. (1) 109–121
Gueugnon, M., see Nguyen, M.-F. (1) 123–137
Haanpää, R.M., see Suhonen, N.-M. (2) 479–489
Halliday, G.M., see Van Langenhove, T. (1) 163–170
Halliday, G.M., see Yang, Y. (3) 701–709
Hameed, S., see Tan, Y.J. (2) 413–423
Han, B., see Yilmaz, A. (2) 355–359
Han, J., see Tian, S. (4) 1163–1173
Han, Y., see Li, Y. (4) 1175–1187
Hänninen, T., see Suhonen, N.-M. (2) 479–489
Harding, A., S. Robinson, S. Crean and S.K. Singhrao, Can Better Management of Periodontal Disease Delay the Onset and Progression of Alzheimer’s Disease? (2) 337–348
Harkness, K., see Mirheidari, B. (2) 373–387
Harrington, K., see Gardener, S.L. (1) 193–201
Harris, W.S., see Amen, D.G. (4) 1189–1199
Hartig, R., see Busse, M. (4) 1303–1313
Hartikainen, P., see Suhonen, N.-M. (2) 479–489
Hawley, N., see Ritter, A. (3) 695–699
Head, D., see Babulal, G.M. (3) 675–680
Heath, M., see Shellington, E.M. (1) 17–22
Heikkinen, A.-L., see Suhonen, N.-M. (2) 479–489
Helisalmi, S., see Suhonen, N.-M. (2) 479–489
Henriques, A.G., see Oliveira, J. (4) 953–978
Herman, S.T., see Musaeus, C.S. (4) 1065–1076
Hermann, B.P., see Dougherty, R.J. (4) 1089–1097
Hernández, A.M., see Ochoa, J.F. (4) 1229–1244
Hernández, I., see Cañabate, P. (4) 1099–1108
Herrmann, N., see Suridjan, I. (3) 885–896
Hibbs, E., see Kehoe, P.G. (1) 203–214
Hiltunen, M., see Suhonen, N.-M. (2) 479–489
Hirokawa, K., see Kasahata, N. (3) 681–685
Hodges, J.R., see Van Langenhove, T. (1) 163–170
Hodges, J.R., see Yang, Y. (3) 701–709
Holtzman, D.M., see Babulal, G.M. (3) 675–680
Howard, R., see Orgeta, V. (3) 725–733
Hsiung, G.-Y.R., see Sepehry, A.A. (2) 449–462
Hua, D.H., see Maezawa, I. (2) 559–574
Huang, P., see Jiang, C. (1) 1–15
Huang, R., see Tian, S. (4) 1163–1173
Huang, Y., see Van Langenhove, T. (1) 163–170
Hubbard, R.A., see Dublin, S. (2) 435–448
Hui, I., see Chan, S.C.C. (3) 735–746
Huisman, M., see Vos, S.J.B. (2) 537–547
Hüll, M., see Wolfsgruber, S. (3) 939–950
Huntley, M.L., see Siedlak, S.L. (4) 1027–1033
Idland, A.-V., see Sala-Llonch, R. (3) 829–840
Iga, J.-I., see Yoshino, Y. (3) 687–694
Iinuma, K.M., see Nakamura, N. (4) 1151–1161
Illán-Gala, I., see Sala, I. (3) 909–918
Imam, K., see Yilmaz, A. (2) 355–359
Imamura, T., see Nakamura, N. (4) 1151–1161
Insua, D., see Lacosta, A.-M. (3) 661–667
Iqbal, K., see Baazaoui, N. (1) 215–230
Irving, K., see Vos, S.J.B. (2) 537–547
Itorralba, J., see Garcia, A. (1) 139–145
Ivachtchenko, A.V., I. Okun, V. Aladinskiy, Y. Ivanenkov, A. Koryakova, R. Karapetyan, O. Mitkin, R. Salimov and A. Ivashchenko, AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation (4) 1043–1063
Ivanenkov, Y., see Ivachtchenko, A.V. (4) 1043–1063
Ivashchenko, A., see Ivachtchenko, A.V. (4) 1043–1063
Iwata, Y., see Chung, J.K. (3) 747–762
Jack Jr., C.R., see Pink, A. (4) 1273–1281
Jacob, L., see Bohlken, J. (1) 37–44
Jacova, C., see Sepehry, A.A. (2) 449–462
Jadhav, S., see Skrabana, R. (4) 1017–1025
Jagust, W., see Liu, C.Y. (4) 1035–1041
Jang, J.-W., see Moon, B. (4) 1255–1264
Jary, E., see Van Langenhove, T. (1) 163–170
Jassal, S.K., see Laughlin, G.A. (3) 871–883
Jessen, F., see Wolfsgruber, S. (3) 939–950
Ji, F., see Tan, Y.J. (2) 413–423
Jiang, C., G. Li, P. Huang, Z. Liu and B. Zhao, The Gut Microbiota and Alzheimer’s Disease (1) 1–15
Jiang, L., see Xie, B. (1) 263–274
Jiang, Y., see Siedlak, S.L. (4) 1027–1033
Jin, L.-W., see Liu, C.Y. (4) 1035–1041
Jin, L.-W., see Maezawa, I. (2) 559–574
Jin, W.-S., X.-L. Bu, Y.-R. Wang, L. Li, W.-W. Li, Y.-H. Liu, C. Zhu, X.-Q. Yao, Y. Chen, C.-Y. Gao, T. Zhang, H.-D. Zhou, F. Zeng and Y.-J. Wang, Reduced Cardiovascular Functions in Patients with Alzheimer’s Disease (3) 919–925
Jing, B., see Li, Y. (4) 1175–1187
Johnell, K., see Cermakova, P. (4) 1265–1272
Johnson, S.C., see Dougherty, R.J. (4) 1089–1097
Jokelainen, J., see Suhonen, N.-M. (2) 479–489
Jukema, J.W., see Mahinrad, S. (1) 275–283
Kalaw, M.C., see Garcia, A. (1) 139–145
Kandiah, N., see Tan, Y.J. (2) 413–423
Karapetyan, R., see Ivachtchenko, A.V. (4) 1043–1063
Karmakar, S., see Tripathi, A.K. (4) 1109–1119
Kasahata, N., T. Sato, I. Onishi, M. Kitagawa, T. Uchihara and K. Hirokawa, Three-Repeat Tau with Grain-Like Structures and Distribution in an 83-Year-Old Man (3) 681–685
Katina, S., see Majerova, P. (2) 507–520
Kayed, R., see Kolarova, M. (2) 471–478
Kehoe, P.G., E. Hibbs, L.E. Palmer and J.S. Miners, Angiotensin-III is Increased in Alzheimer’s Disease in Association with Amyloid-β and Tau Pathology (1) 203–214
Kero, M., see Raunio, A. (3) 669–674
Kesslak, P., see Rafii, M.S. (2) 401–411
Khan, T., see Nelson, T.J. (2) 521–535
Khondoker, M., S.B. Rafnsson, S. Morris, M. Orrell and A. Steptoe, Positive and Negative Experiences of Social Support and Risk of Dementia in Later Life: An Investigation Using the English Longitudinal Study of Ageing (1) 99–108
Khutsyan, S., see Gordon, R. (3) 711–724
Kidd, P.M., see Amen, D.G. (4) 1189–1199
Kilander, L., see Cermakova, P. (4) 1265–1272
Kim, D.-H., see An, H. (1) 253–261
Kim, J., see Chung, J.K. (3) 747–762
Kim, S., see Deters, K.D. (4) 1245–1254
Kim, S., see Moon, B. (4) 1255–1264
Kim, S.Y., see Moon, B. (4) 1255–1264
Kim, W.S., see Van Langenhove, T. (1) 163–170
Kira, J.-i., see Nakamura, N. (4) 1151–1161
Kirby, T.K., see Dougherty, R.J. (4) 1089–1097
Kitagawa, M., see Kasahata, N. (3) 681–685
Kleineidam, L., see Wolfsgruber, S. (3) 939–950
Knopman, D.S., see Pink, A. (4) 1273–1281
Köhler, S., see Vos, S.J.B. (2) 537–547
Kolarova, M., U. Sengupta, A. Bartos, J. Ricny and R. Kayed, Tau Oligomers in Sera of Patients with Alzheimer’s Disease and Aged Controls (2) 471–478
Kontsekova, E., see Skrabana, R. (4) 1017–1025
Koppara, A., see Wolfsgruber, S. (3) 939–950
Korhonen, V., see Suhonen, N.-M. (2) 479–489
Kornhuber, J., see Wolfsgruber, S. (3) 939–950
Koryakova, A., see Ivachtchenko, A.V. (4) 1043–1063
Kostev, K., see Bohlken, J. (1) 37–44
Kovac, A., see Majerova, P. (2) 507–520
Kovacech, B., see Skrabana, R. (4) 1017–1025
Kraner, S.D., see Manocha, G.D. (3) 775–787
Krell-Roesch, J., see Pink, A. (4) 1273–1281
Kristt, D., see Pinner, E. (4) 1137–1149
Kritz-Silverstein, D., see Laughlin, G.A. (3) 871–883
Krüger, J., see Suhonen, N.-M. (2) 479–489
Kunschmann, R., S. Busse, T. Frodl and M. Busse, Psychotic Symptoms Associated with Poor Renal Function in Mild Cognitive Impairment and Dementias (1) 243–252
Kwok, J.B., see Van Langenhove, T. (1) 163–170
Lacosta, A.-M., D. Insua, H. Badi, P. Pesini and M. Sarasa, Neurofibrillary Tangles of Aβx-40 in Alzheimer’s Disease Brains (3) 661–667
Laine, M., see Tort-Merino, A. (3) 855–870
Lam, L.C.W., see Lu, H. (3) 927–937
Lanctôt, K.L., see Suridjan, I. (3) 885–896
Larson, E.B., see Dublin, S. (2) 435–448
Lau, S.C.L., see Chan, S.C.C. (3) 735–746
Laudon, M., see Pinner, E. (4) 1137–1149
Laughlin, G.A., D. Kritz-Silverstein, J. Bergstrom, E.T. Reas, S.K. Jassal, E. Barrett-Connor and L.K. McEvoy, Vitamin D Insufficiency and Cognitive Function Trajectories in Older Adults: The Rancho Bernardo Study (3) 871–883
Laws, S.M., see Lim, Y.Y. (4) 1293–1302
Lee, L., see Sadiq, D. (2) 463–470
Lee, P.E., see Sepehry, A.A. (2) 449–462
Lee, T.-S., see Tan, Y.J. (2) 413–423
León, M., see Tort-Merino, A. (3) 855–870
Lewczuk, P., see Wolfsgruber, S. (3) 939–950
Leyton, C., see Van Langenhove, T. (1) 163–170
Li, G., see Jiang, C. (1) 1–15
Li, K., W. Chan, R.S. Doody, J. Quinn and S. Luo the Alzheimer’s Disease Neuroimaging Initiative, Prediction of Conversion to Alzheimer’s Disease with Longitudinal Measures and Time-To-Event Data (2) 361–371
Li, L., see Jin, W.-S. (3) 919–925
Li, L., see Li, Q. (2) 549–558
Li, Q., J. Cui, C. Fang, M. Liu, G. Min and L. Li, S-Adenosylmethionine Attenuates Oxidative Stress and Neuroinflammation Induced by Amyloid-β Through Modulation of Glutathione Metabolism (2) 549–558
Li, W.-W., see Jin, W.-S. (3) 919–925
Li, Y., B. Jing, H. Liu, Y. Li, X. Gao, Y. Li, B. Mu, H. Yu, J. Cheng, P.B. Barker, H. Wang and Y. Han, Frequency-Dependent Changes in the Amplitude of Low-Frequency Fluctuations in Mild Cognitive Impairment with Mild Depression (4) 1175–1187
Li, Y., see Li, Y. (4) 1175–1187
Li, Y., see Li, Y. (4) 1175–1187
Lim, C., see Nelson, T.J. (2) 521–535
Lim, J.K.W., see Tan, Y.J. (2) 413–423
Lim, J.-S., see Moon, B. (4) 1255–1264
Lim, Y.Y., R. Williamson, S.M. Laws, V.L. Villemagne, P. Bourgeat, C. Fowler, S. Rainey-Smith, O. Salvado, R.N. Martins, C.C. Rowe, C.L. Masters and P. Maruff for the AIBL Research Group, Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals (4) 1293–1302
Lim, Y.Y., see Gardener, S.L. (1) 193–201
Liu, C.Y., Y. Ohki, T. Tomita, S. Osawa, B.R. Reed, W. Jagust, V. Van Berlo, L.-W. Jin, H.C. Chui, G. Coppola and J.M. Ringman, Two Novel Mutations in the First Transmembrane Domain of Presenilin1 Cause Young-Onset Alzheimer’s Disease (4) 1035–1041
Liu, G., J.-y. Sun, M. Xu, X.-y. Yang and B.-l. Sun, SORL1 Variants Show Different Association with Early-Onset and Late-Onset Alzheimer’s Disease Risk (4) 1121–1128
Liu, H., see Li, Y. (4) 1175–1187
Liu, J., see Siedlak, S.L. (4) 1027–1033
Liu, M., see Li, Q. (2) 549–558
Liu, W., see Xie, B. (1) 263–274
Liu, Y.-H., see Jin, W.-S. (3) 919–925
Liu, Z., see Jiang, C. (1) 1–15
Liu, Z., see Xie, B. (1) 263–274
Livingston, G., see Mukadam, N. (1) 45–54
Lleó, A., see Sala, I. (3) 909–918
Lopera, F., see Ochoa, J.F. (4) 1229–1244
López-Higes, R., I.C. Rodríguez-Rojo, J.M. Prados, P. Montejo, D. Del-Río, M.L. Delgado-Losada, M. Montenegro, D. López-Sanz and A. Barabash, APOE ɛ4 Modulation of Training Outcomes in Several Cognitive Domains in a Sample of Cognitively Intact Older Adults (4) 1201–1215
López-Sanz, D., see López-Higes, R. (4) 1201–1215
Lorente-Gea, L., see García, B. (1) 185–192
Lott, I.T., see Rafii, M.S. (2) 401–411
Lu, H., S.S.M. Chan, A.W.T. Fung and L.C.W. Lam, Beyond a Differential Diagnosis: Cognitive and Morphometric Decoding of Information Processing Speed in Senior Adults with DSM-5 Mild Neurocognitive Disorders (3) 927–937
Lu, S., see Malek-Ahmadi, M. (2) 575–583
Luedke, A., see Garcia, A. (1) 139–145
Luo, S., see Li, K. (2) 361–371
Macaulay, S.L., see Gardener, S.L. (1) 193–201
Macdonald, I.R., S.P. Maxwell, G.A. Reid, M.K. Cash, D.R. DeBay and S. Darvesh, Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer’s Disease (2) 491–505
Macedo, A.C., S. Balouch and N. Tabet, Is Sleep Disruption a Risk Factor for Alzheimer’s Disease? (4) 993–1002
Macfarlane, P.W., see Mahinrad, S. (1) 275–283
Maddens, M., see Yilmaz, A. (2) 355–359
Maezawa, I., B. Zou, J. Di Lucente, W.S. Cao, C. Pascual, S. Weerasekara, M. Zhang, X.S. Xie, D.H. Hua and L.-W. Jin, The Anti-Amyloid-β and Neuroprotective Properties of a Novel Tricyclic Pyrone Molecule (2) 559–574
Mahinrad, S., A.E. Vriend, J.W. Jukema, D. van Heemst, N. Sattar, G.J. Blauw, P.W. Macfarlane, E.N. Clark, A.J.M. de Craen and B. Sabayan, Left Ventricular Hypertrophy and Cognitive Decline in Old Age (1) 275–283
Mai, S., see Garcia, A. (1) 139–145
Maier, W., see Wolfsgruber, S. (3) 939–950
Majerova, P., P. Barath, A. Michalicova, S. Katina, M. Novak and A. Kovac, Changes of Cerebrospinal Fluid Peptides due to Tauopathy (2) 507–520
Makarova, E., see Gordon, R. (3) 711–724
Malek-Ahmadi, M., S. Lu, Y. Chan, S.E. Perez, K. Chen and E.J. Mufson, Cognitive Domain Dispersion Association with Alzheimer’s Disease Pathology (2) 575–583
Mañanas, M.A., see Ochoa, J.F. (4) 1229–1244
Manczak, M., see Reddy, P.H. (1) 147–162
Mannino, M., see Nave, S. (4) 1217–1228
Manocha, G.D., A. Ghatak, K.L. Puig, S.D. Kraner, C.M. Norris and C.K. Combs, NFATc2 Modulates Microglial Activation in the AβPP/PS1 Mouse Model of Alzheimer’s Disease (3) 775–787
Marra, C., see Serra, L. (1) 171–184
Martín, C., see García, B. (1) 185–192
Martín, E., see Cañabate, P. (4) 1099–1108
Martin, M., see Snow, W.M. (3) 841–853
Martínez, G., see Cañabate, P. (4) 1099–1108
Martínez-Lage, P., see Tort-Merino, A. (3) 855–870
Martins, R.N., see Gardener, S.L. (1) 193–201
Martins, R.N., see Lim, Y.Y. (4) 1293–1302
Maruff, P., see Gardener, S.L. (1) 193–201
Maruff, P., see Lim, Y.Y. (4) 1293–1302
Masters, C.L., see Gardener, S.L. (1) 193–201
Masters, C.L., see Lim, Y.Y. (4) 1293–1302
Mathur, S., see Garcia, A. (1) 139–145
Mauleón, A., see Cañabate, P. (4) 1099–1108
Maxwell, S.P., see Macdonald, I.R. (2) 491–505
McAvoy, E., see Garcia, A. (1) 139–145
McConnell, I., see Swanson, E. (3) 803–820
McDonough, M.E., see Rafii, M.S. (2) 401–411
McEvoy, L.K., see Laughlin, G.A. (3) 871–883
McMahon, L., see Swanson, E. (3) 803–820
Mecocci, P., see Paolacci, L. (2) 323–335
Merayo-Lloves, J., see García, B. (1) 185–192
Meysami, S., see Amen, D.G. (4) 1189–1199
Michalicova, A., see Majerova, P. (2) 507–520
Michler, E., see Busse, M. (4) 1303–1313
Mielke, M.M., see Pink, A. (4) 1273–1281
Miles, J.M., see Morris, J.K. (4) 1129–1135
Miller, J.B., see Ritter, A. (3) 695–699
Min, G., see Li, Q. (2) 549–558
Miners, J.S., see Kehoe, P.G. (1) 203–214
Mirheidari, B., D. Blackburn, K. Harkness, T. Walker, A. Venneri, M. Reuber and H. Christensen, Toward the Automation of Diagnostic Conversation Analysis in Patients with Memory Complaints (2) 373–387
Mitkin, O., see Ivachtchenko, A.V. (4) 1043–1063
Molinuevo, J.L., see Tort-Merino, A. (3) 855–870
Montejo, P., see López-Higes, R. (4) 1201–1215
Montenegro, M., see López-Higes, R. (4) 1201–1215
Montine, T.J., see Dublin, S. (2) 435–448
Moon, B., S. Kim, Y.H. Park, J.-S. Lim, Y.C. Youn, S. Kim and J.-W. Jang, for the Alzheimer’s Disease Neuroimaging Initiative, Depressive Symptoms are Associated with Progression to Dementia in Patients with Amyloid-Positive Mild Cognitive Impairment (4) 1255–1264
Moran, E., see Nave, S. (4) 1217–1228
Morenas-Rodríguez, E., see Sala, I. (3) 909–918
Moreno, M., see Cañabate, P. (4) 1099–1108
Mori, T., see Yoshino, Y. (3) 687–694
Mori, Y., see Yoshino, Y. (3) 687–694
Morris, J.C., see Babulal, G.M. (3) 675–680
Morris, J.K., R.A.Z. Uy, E.D. Vidoni, H.M. Wilkins, A.E. Archer, J.P. Thyfault, J.M. Miles and J.M. Burns, Effect of APOE ɛ4 Genotype on Metabolic Biomarkers in Aging and Alzheimer’s Disease (4) 1129–1135
Morris, S., see Khondoker, M. (1) 99–108
Motohashi, N., see Yamazaki, C. (2) 349–354
Mu, B., see Li, Y. (4) 1175–1187
Muelhardt, N.M., see Nave, S. (4) 1217–1228
Mufson, E.J., see Malek-Ahmadi, M. (2) 575–583
Mugantseva, E., see Gordon, R. (3) 711–724
Mukadam, N., A. Sommerlad and G. Livingston, The Relationship of Bilingualism Compared to Monolingualism to the Risk of Cognitive Decline or Dementia: A Systematic Review and Meta-Analysis (1) 45–54
Muñiz-Alonso, B., see García, B. (1) 185–192
Murai, H., see Nakamura, N. (4) 1151–1161
Muranevici, G., see Rafii, M.S. (2) 401–411
Murashev, A., see Gordon, R. (3) 711–724
Musaeus, C.S., M.M. Shafi, E. Santarnecchi, S.T. Herman and D.Z. Press, Levetiracetam Alters Oscillatory Connectivity in Alzheimer’s Disease (4) 1065–1076
Myers, N.E., see Pasquini, L. (3) 763–773
Myllykangas, L., see Raunio, A. (3) 669–674
Nakajima, S., see Chung, J.K. (3) 747–762
Nakamura, N., Y. Ohyagi, T. Imamura, Y.T. Yanagihara, K.M. Iinuma, N. Soejima, H. Murai, R. Yamasaki and J.-i. Kira, Apomorphine Therapy for Neuronal Insulin Resistance in a Mouse Model of Alzheimer’s Disease (4) 1151–1161
Naor, D., see Pinner, E. (4) 1137–1149
Nave, S., R.S. Doody, M. Boada, T. Grimmer, J.-M. Savola, P. Delmar, M. Pauly-Evers, T. Nikolcheva, C. Czech, E. Borroni, B. Ricci, J. Dukart, M. Mannino, T. Carey, E. Moran, I. Gilaberte, N.M. Muelhardt, I. Gerlach, L. Santarelli, S. Ostrowitzki and P. Fontoura, Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD) (4) 1217–1228
Nelson, M., see Cermakova, P. (4) 1265–1272
Nelson, T.J., M.-K. Sun, C. Lim, A. Sen, T. Khan, F.V. Chirila and D.L. Alkon, Bryostatin Effects on Cognitive Function and PKCɛ in Alzheimer’s Disease Phase IIa and Expanded Access Trials (2) 521–535
Ng, A.S.L., see Tan, Y.J. (2) 413–423
Nguyen, M.-F., M. Bonnefoy, A. Adrait, M. Gueugnon, C. Petitot, L. Collet, A. Roux and X. Perrot on behalf of the ADPHA study group, Efficacy of Hearing Aids on the Cognitive Status of Patients with Alzheimer’s Disease and Hearing Loss: A Multicenter Controlled Randomized Trial (1) 123–137
Nguyen, M.-F., see Adrait, A. (1) 109–121
Nho, K., see Deters, K.D. (4) 1245–1254
Nikolcheva, T., see Nave, S. (4) 1217–1228
Nilforooshan, R., see Orgeta, V. (3) 725–733
Norris, C.M., see Manocha, G.D. (3) 775–787
Novak, M., see Majerova, P. (2) 507–520
Novak, M., see Skrabana, R. (4) 1017–1025
Nunomura, A., see Yamazaki, C. (2) 349–354
O’Brien-Moran, Z., see Snow, W.M. (3) 841–853
O’Donnell, C.A., see Vos, S.J.B. (2) 537–547
O’Driscoll, C. and M. Shaikh, Cross-Cultural Applicability of the Montreal Cognitive Assessment (MoCA): A Systematic Review (3) 789–801
Ochi, S., see Yoshino, Y. (3) 687–694
Ochoa, J.F., J.F. Alonso, J.E. Duque, C.A. Tobón, A. Baena, F. Lopera, M.A. Mañanas and A.M. Hernández, Precuneus Failures in Subjects of the PSEN1 E280A Family at Risk of Developing Alzheimer’s Disease Detected Using Quantitative Electroencephalography (4) 1229–1244
Offen, D., see Segal-Gavish, H. (2) 389–400
Oh, J.M., see Dougherty, R.J. (4) 1089–1097
Oh, P.I., see Suridjan, I. (3) 885–896
Ohki, Y., see Liu, C.Y. (4) 1035–1041
Ohyagi, Y., see Nakamura, N. (4) 1151–1161
Oinas, M., see Raunio, A. (3) 669–674
Okonkwo, O.C., see Dougherty, R.J. (4) 1089–1097
Okun, I., see Ivachtchenko, A.V. (4) 1043–1063
Oliveira, J., M. Costa, M.S.C. de Almeida, O.A.B. da Cruz e Silva and A.G. Henriques, Protein Phosphorylation is a Key Mechanism in Alzheimer’s Disease (4) 953–978
Olives, J., see Tort-Merino, A. (3) 855–870
Onishi, I., see Kasahata, N. (3) 681–685
Ordiales, H., see García, B. (1) 185–192
Orgeta, V., N. Tabet, R. Nilforooshan and R. Howard, Efficacy of Antidepressants for Depression in Alzheimer’s Disease: Systematic Review and Meta-Analysis (3) 725–733
Orrell, M., see Khondoker, M. (1) 99–108
Ortega, G., see Cañabate, P. (4) 1099–1108
Osawa, S., see Liu, C.Y. (4) 1035–1041
Ostrowitzki, S., see Nave, S. (4) 1217–1228
Ozaki, Y., see Yoshino, Y. (3) 687–694
Paetau, A., see Raunio, A. (3) 669–674
Palmer, L.E., see Kehoe, P.G. (1) 203–214
Pang, M.Y.C., see Chan, S.C.C. (3) 735–746
Paolacci, L., D. Giannandrea, P. Mecocci and L. Parnetti, Biomarkers for Early Diagnosis of Alzheimer’s Disease in the Oldest Old: Yes or No? (2) 323–335
Park, Y.H., see Moon, B. (4) 1255–1264
Parnetti, L., see Paolacci, L. (2) 323–335
Pascual, C., see Maezawa, I. (2) 559–574
Pasquini, L., G. Benson, M.J. Grothe, L. Utz, N.E. Myers, I. Yakushev, T. Grimmer, M. Scherr and C. Sorg for the Alzheimer’s Disease Neuroimaging Initiative, Individual Correspondence of Amyloid-β and Intrinsic Connectivity in the Posterior Default Mode Network Across Stages of Alzheimer’s Disease (3) 763–773
Patel, R., see Chung, J.K. (3) 747–762
Pauly-Evers, M., see Nave, S. (4) 1217–1228
Peirson, D., see Snow, W.M. (3) 841–853
Peñaloza, C., see Tort-Merino, A. (3) 855–870
Peres, K., see Vos, S.J.B. (2) 537–547
Perez, S.E., see Malek-Ahmadi, M. (2) 575–583
Perneczky, R., see Robb, C. (1) 69–78
Perrot, X., see Adrait, A. (1) 109–121
Perrot, X., see Nguyen, M.-F. (1) 123–137
Perry, G., see Siedlak, S.L. (4) 1027–1033
Pertl, M.-T., T. Benke, L. Zamarian and M. Delazer, Effects of Healthy Aging and Mild Cognitive Impairment on a Real-Life Decision-Making Task (4) 1077–1087
Pesini, P., see Lacosta, A.-M. (3) 661–667
Peters, O., see Wolfsgruber, S. (3) 939–950
Petersen, R.C., see Pink, A. (4) 1273–1281
Petitot, C., see Adrait, A. (1) 109–121
Petitot, C., see Nguyen, M.-F. (1) 123–137
Petrella, R.J., see Shellington, E.M. (1) 17–22
Piguet, O., see Van Langenhove, T. (1) 163–170
Pink, A., S.A. Przybelski, J. Krell-Roesch, G.B. Stokin, R.O. Roberts, M.M. Mielke, D.S. Knopman, C.R. Jack Jr., R.C. Petersen and Y.E. Geda, Cortical Thickness and Depressive Symptoms in Cognitively Normal Individuals: The Mayo Clinic Study of Aging (4) 1273–1281
Pinner, E., Y. Gruper, M. Ben Zimra, D. Kristt, M. Laudon, D. Naor and N. Zisapel, CD44 Splice Variants as Potential Players in Alzheimer’s Disease Pathology (4) 1137–1149
Pisa, D., see Alonso, R. (1) 55–67
Pitkäniemi, A., see Suhonen, N.-M. (2) 479–489
Plitman, E., see Chung, J.K. (3) 747–762
Podolski, I., see Gordon, R. (3) 711–724
Polcher, A., see Wolfsgruber, S. (3) 939–950
Polvikoski, T., see Raunio, A. (3) 669–674
Prados, J.M., see López-Higes, R. (4) 1201–1215
Preckler, S., see Cañabate, P. (4) 1099–1108
Press, D.Z., see Musaeus, C.S. (4) 1065–1076
Przybelski, S.A., see Pink, A. (4) 1273–1281
Puig, K.L., see Manocha, G.D. (3) 775–787
Pulsifer, M., see Rafii, M.S. (2) 401–411
Qiu, Y., see Tan, Y.J. (2) 413–423
Quinn, J., see Li, K. (2) 361–371
Quirós, L.M., see García, B. (1) 185–192
Rafii, M.S., B.G. Skotko, M.E. McDonough, M. Pulsifer, C. Evans, E. Doran, G. Muranevici, P. Kesslak, S. Abushakra and I.T. Lott for the ELND005-DS Study Group, A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia (2) 401–411
Rafnsson, S.B., see Khondoker, M. (1) 99–108
Rainey-Smith, S., see Lim, Y.Y. (4) 1293–1302
Rainey-Smith, S.R., see Gardener, S.L. (1) 193–201
Raji, C.A., see Amen, D.G. (4) 1189–1199
Rami, L., see Tort-Merino, A. (3) 855–870
Ramirez, J., see Berezuk, C. (2) 425–434
Raunio, A., L. Myllykangas, M. Kero, T. Polvikoski, A. Paetau and M. Oinas, Amygdala α-Synuclein Pathology in the Population-Based Vantaa 85+ Study (3) 669–674
Reas, E.T., see Laughlin, G.A. (3) 871–883
Recio, M., see de Eulate, R.G. (2) 585–595
Reddy, P.H., M. Manczak and X. Yin, Mitochondria-Division Inhibitor 1 Protects Against Amyloid-β induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer’s Disease (1) 147–162
Reed, B.R., see Liu, C.Y. (4) 1035–1041
Reid, G.A., see Macdonald, I.R. (2) 491–505
Religa, D., see Cermakova, P. (4) 1265–1272
Remes, A.M., see Suhonen, N.-M. (2) 479–489
Ren, Q., see Sun, J. (3) 597–612
Reuber, M., see Mirheidari, B. (2) 373–387
Ribosa-Nogué, R., see Sala, I. (3) 909–918
Ricci, B., see Nave, S. (4) 1217–1228
Ricny, J., see Kolarova, M. (2) 471–478
Ringman, J.M., see Liu, C.Y. (4) 1035–1041
Risacher, S.L., see Deters, K.D. (4) 1245–1254
Ritchie, K., see Vos, S.J.B. (2) 537–547
Ritter, A., N. Hawley, S.J. Banks and J.B. Miller, The Association between Montreal Cognitive Assessment Memory Scores and Hippocampal Volume in a Neurodegenerative Disease Sample (3) 695–699
Riverol, M., see de Eulate, R.G. (2) 585–595
Robb, C., C. Udeh-Momoh, S. Wagenpfeil, J. Schöpe, P. Alexopoulos and R. Perneczky for the Alzheimer’s Disease Neuroimaging Initiative, Biomarkers and Functional Decline in Prodromal Alzheimer’s Disease (1) 69–78
Roberts, R.O., see Pink, A. (4) 1273–1281
Robinson, S., see Harding, A. (2) 337–348
Rockwood, K., see Godin, J. (1) 231–242
Rodríguez, O., see Cañabate, P. (4) 1099–1108
Rodríguez-Fornells, A., see Tort-Merino, A. (3) 855–870
Rodríguez-Rojo, I.C., see López-Higes, R. (4) 1201–1215
Roe, C.M., see Babulal, G.M. (3) 675–680
Rosenberry, T.L., see Williams, S.M. (1) 23–35
Rosende-Roca, M., see Cañabate, P. (4) 1099–1108
Roux, A., see Adrait, A. (1) 109–121
Roux, A., see Nguyen, M.-F. (1) 123–137
Rowe, C.C., see Gardener, S.L. (1) 193–201
Rowe, C.C., see Lim, Y.Y. (4) 1293–1302
Ruiz, A., see Cañabate, P. (4) 1099–1108
Ruiz-Díaz, I., see García, B. (1) 185–192
Ruocco, A.C., see Berezuk, C. (2) 425–434
Rüther, E., see Wolfsgruber, S. (3) 939–950
Sabayan, B., see Mahinrad, S. (1) 275–283
Sacuiu, S.F., see Vos, S.J.B. (2) 537–547
Sadiq, D., T. Whitfield, L. Lee, T. Stevens, S. Costafreda and Z. Walker, Prodromal Dementia with Lewy Bodies and Prodromal Alzheimer’s Disease: A Comparison of the Cognitive and Clinical Profiles (2) 463–470
Sager, M.A., see Dougherty, R.J. (4) 1089–1097
Sala, I., I. Illán-Gala, D. Alcolea, M.B. Sánchez-Saudinós, S.A. Salgado, E. Morenas-Rodríguez, A. Subirana, L. Videla, J. Clarimón, M. Carmona-Iragui, R. Ribosa-Nogué, R. Blesa, J. Fortea and A. Lleó, Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer’s Disease (3) 909–918
Sala-Llonch, R., A.-V. Idland, T. Borza, L.O. Watne, T.B. Wyller, A. Brækhus, H. Zetterberg, K. Blennow, K.B. Walhovd and A.M. Fjell, Inflammation, Amyloid, and Atrophy in The Aging Brain: Relationships with Longitudinal Changes in Cognition (3) 829–840
Saleem, M., see Suridjan, I. (3) 885–896
Salgado, S.A., see Sala, I. (3) 909–918
Salimov, R., see Ivachtchenko, A.V. (4) 1043–1063
Salvado, O., see Lim, Y.Y. (4) 1293–1302
Sánchez, D., see Cañabate, P. (4) 1099–1108
Sánchez-Saudinós, M.B., see Sala, I. (3) 909–918
Santarelli, L., see Nave, S. (4) 1217–1228
Santarnecchi, E., see Musaeus, C.S. (4) 1065–1076
Santos-Juanes, J., see García, B. (1) 185–192
Sao, T., see Yoshino, Y. (3) 687–694
Sarasa, M., see Lacosta, A.-M. (3) 661–667
Sato, T., see Kasahata, N. (3) 681–685
Sattar, N., see Mahinrad, S. (1) 275–283
Savola, J.-M., see Nave, S. (4) 1217–1228
Saykin, A.J., see Deters, K.D. (4) 1245–1254
Scafato, E., see Vos, S.J.B. (2) 537–547
Scherr, M., see Pasquini, L. (3) 763–773
Schiepers, O.J.G., see Vos, S.J.B. (2) 537–547
Schöpe, J., see Robb, C. (1) 69–78
Schultz, S.A., see Dougherty, R.J. (4) 1089–1097
Schulz, P., see Williams, S.M. (1) 23–35
Secnik, J., see Cermakova, P. (4) 1265–1272
Segal-Gavish, H., O. Danino, Y. Barhum, T. Ben-Zur, E. Shai, D. Varon, D. Offen and B. Fischer, A Multifunctional Biocompatible Drug Candidate is Highly Effective in Delaying Pathological Signs of Alzheimer’s Disease in 5XFAD Mice (2) 389–400
Sen, A., see Nelson, T.J. (2) 521–535
Sengpiel, F., see Gordon, R. (3) 711–724
Sengupta, U., see Kolarova, M. (2) 471–478
Sepehry, A.A., P.E. Lee, G.-Y.R. Hsiung, B.L. Beattie, H.H. Feldman and C. Jacova, The 2002 NIMH Provisional Diagnostic Criteria for Depression of Alzheimer’s Disease (PDC-dAD): Gauging their Validity over a Decade Later (2) 449–462
Serra, L., M. Bruschini, C. Di Domenico, G.B. Gabrielli, C. Marra, C. Caltagirone, M. Cercignani and M. Bozzali, Memory is Not Enough: The Neurobiological Substrates of Dynamic Cognitive Reserve (1) 171–184
Shafi, M.M., see Musaeus, C.S. (4) 1065–1076
Shai, E., see Segal-Gavish, H. (2) 389–400
Shaikh, M., see O’Driscoll, C. (3) 789–801
Shaw, L.M., see Deters, K.D. (4) 1245–1254
Shellington, E.M., M. Heath, D.P. Gill and R.J. Petrella, Long-Term Maintenance of Executive-Related Oculomotor Improvements in Older Adults with Self-Reported Cognitive Complaints Following a 24-Week Multiple Modality Exercise Program (1) 17–22
Shen, Y., see Tian, S. (4) 1163–1173
Shinagawa, S., see Chung, J.K. (3) 747–762
Siedlak, S.L., Y. Jiang, M.L. Huntley, L. Wang, J. Gao, F. Xie, J. Liu, B. Su, G. Perry and X. Wang, TMEM230 Accumulation in Granulovacuolar Degeneration Bodies and Dystrophic Neurites of Alzheimer’s Disease (4) 1027–1033
Sierks, M.R., see Williams, S.M. (1) 23–35
Singh, N., see Tripathi, A.K. (4) 1109–1119
Singhrao, S.K., see Harding, A. (2) 337–348
Skoog, I., see Vos, S.J.B. (2) 537–547
Skotko, B.G., see Rafii, M.S. (2) 401–411
Skrabana, R., B. Kovacech, P. Filipcik, N. Zilka, S. Jadhav, T. Smolek, E. Kontsekova and M. Novak, Neuronal Expression of Truncated Tau Efficiently Promotes Neurodegeneration in Animal Models: Pitfalls of Toxic Oligomer Analysis (4) 1017–1025
Smolek, T., see Skrabana, R. (4) 1017–1025
Snow, W.M., R. Dale, Z. O’Brien-Moran, R. Buist, D. Peirson, M. Martin and B.C. Albensi, In Vivo Detection of Gray Matter Neuropathology in the 3xTg Mouse Model of Alzheimer’s Disease with Diffusion Tensor Imaging (3) 841–853
Soejima, N., see Nakamura, N. (4) 1151–1161
Sohrabi, H.R., see Gardener, S.L. (1) 193–201
Som, S., see Swanson, E. (3) 803–820
Sommerlad, A., see Mukadam, N. (1) 45–54
Sonnen, J.A., see Dublin, S. (2) 435–448
Sorg, C., see Pasquini, L. (3) 763–773
Sotolongo, O., see Cañabate, P. (4) 1099–1108
Steptoe, A., see Khondoker, M. (1) 99–108
Stevens, T., see Sadiq, D. (2) 463–470
Stokin, G.B., see Pink, A. (4) 1273–1281
Stout, S.H., see Babulal, G.M. (3) 675–680
Su, B., see Siedlak, S.L. (4) 1027–1033
Subirana, A., see Sala, I. (3) 909–918
Suhonen, N.-M., R.M. Haanpää, V. Korhonen, J. Jokelainen, A. Pitkäniemi, A.-L. Heikkinen, J. Krüger, P. Hartikainen, S. Helisalmi, M. Hiltunen, T. Hänninen and A.M. Remes, Neuropsychological Profile in the C9ORF72 Associated Behavioral Variant Frontotemporal Dementia (2) 479–489
Sun, B.-l., see Liu, G. (4) 1121–1128
Sun, H., Associations of Spatial Disparities of Alzheimer’s Disease Mortality Rates with Soil Selenium and Sulfur Concentrations and Four Common Risk Factors in the United States (3) 897–907
Sun, J., H. Zhou, F. Bai, Z. Zhang and Q. Ren, Remyelination: A Potential Therapeutic Strategy for Alzheimer’s Disease? (3) 597–612
Sun, J., see Tian, S. (4) 1163–1173
Sun, J.-y., see Liu, G. (4) 1121–1128
Sun, M.-K., see Nelson, T.J. (2) 521–535
Sun, S., see Yuan, X.-Z. (2) 303–322
Sun, Y., see Wang, T. (1) 79–86
Suridjan, I., N. Herrmann, A. Adibfar, M. Saleem, A. Andreazza, P.I. Oh and K.L. Lanctôt, Lipid Peroxidation Markers in Coronary Artery Disease Patients with Possible Vascular Mild Cognitive Impairment (3) 885–896
Swanson, E., L. Breckenridge, L. McMahon, S. Som, I. McConnell and G.S. Bloom, Extracellular Tau Oligomers Induce Invasion of Endogenous Tau into the Somatodendritic Compartment and Axonal Transport Dysfunction (3) 803–820
Tabet, N., see Macedo, A.C. (4) 993–1002
Tabet, N., see Orgeta, V. (3) 725–733
Taddei, K., see Gardener, S.L. (1) 193–201
Taghibiglou, C., see Tang, M. (4) 1003–1016
Takeuchi, H., see Chung, J.K. (3) 747–762
Tamai, K., see Yamazaki, C. (2) 349–354
Tamaoki, T., see Yamazaki, C. (2) 349–354
Tan, C.-C., see Yuan, X.-Z. (2) 303–322
Tan, C.-C., see Zhu, J.-B. (3) 631–659
Tan, D.G.H., see Chan, S.C.C. (3) 735–746
Tan, L., see Yuan, X.-Z. (2) 303–322
Tan, L., see Zhu, J.-B. (3) 631–659
Tan, R.H., see Yang, Y. (3) 701–709
Tan, Y.J., A.S.L. Ng, A. Vipin, J.K.W. Lim, R.J. Chander, F. Ji, Y. Qiu, S.K.S. Ting, S. Hameed, T.-S. Lee, L. Zeng, N. Kandiah and J. Zhou, Higher Peripheral TREM2 mRNA Levels Relate to Cognitive Deficits and Hippocampal Atrophy in Alzheimer’s Disease and Amnestic Mild Cognitive Impairment (2) 413–423
Tang, M. and C. Taghibiglou, The Mechanisms of Action of Curcumin in Alzheimer’s Disease (4) 1003–1016
Tárraga, L., see Cañabate, P. (4) 1099–1108
Thyfault, J.P., see Morris, J.K. (4) 1129–1135
Tian, S., J. Han, R. Huang, J. Sun, R. Cai, Y. Shen and S. Wang, Increased Plasma Homocysteine Level is Associated with Executive Dysfunction in Type 2 Diabetic Patients with Mild Cognitive Impairment (4) 1163–1173
Ting, S.K.S., see Tan, Y.J. (2) 413–423
Tobón, C.A., see Ochoa, J.F. (4) 1229–1244
Tomita, T., see Liu, C.Y. (4) 1035–1041
Tort-Merino, A., N. Valech, C. Peñaloza, P. Grönholm-Nyman, M. León, J. Olives, A. Estanga, M. Ecay-Torres, J. Fortea, P. Martínez-Lage, J.L. Molinuevo, M. Laine, A. Rodríguez-Fornells and L. Rami, Early Detection of Learning Difficulties when Confronted with Novel Information in Preclinical Alzheimer’s Disease Stage 1 (3) 855–870
Touchon, J., see Bennys, K. (1) 87–97
Tripathi, A.K., S. Karmakar, A. Asthana, A. Ashok, V. Desai, S. Baksi and N. Singh, Transport of Non-Transferrin Bound Iron to the Brain: Implications for Alzheimer’s Disease (4) 1109–1119
Trojanowski, J.Q., see Deters, K.D. (4) 1245–1254
Tullberg, M., see Edsbagge, M. (3) 821–828
Uchihara, T., see Kasahata, N. (3) 681–685
Udeh-Momoh, C., see Robb, C. (1) 69–78
Ueno, S.-I., see Yoshino, Y. (3) 687–694
Utz, L., see Pasquini, L. (3) 763–773
Uy, R.A.Z., see Morris, J.K. (4) 1129–1135
Valech, N., see Tort-Merino, A. (3) 855–870
Valero, S., see Cañabate, P. (4) 1099–1108
Van Berlo, V., see Liu, C.Y. (4) 1035–1041
van Boxtel, M.P.J., see Vos, S.J.B. (2) 537–547
van Heemst, D., see Mahinrad, S. (1) 275–283
Van Langenhove, T., O. Piguet, J.R. Burrell, C. Leyton, D. Foxe, M. Abela, L. Bartley, W.S. Kim, E. Jary, Y. Huang, C. Dobson-Stone, J.B. Kwok, G.M. Halliday and J.R. Hodges, Predicting Development of Amyotrophic Lateral Sclerosis in Frontotemporal Dementia (1) 163–170
Vargas, L., see Cañabate, P. (4) 1099–1108
Varon, D., see Segal-Gavish, H. (2) 389–400
Vega, I.E., L.Y. Cabrera, C.M. Wygant, D. Velez-Ortiz and S.E. Counts, Alzheimer’s Disease in the Latino Community: Intersection of Genetics and Social Determinants of Health (4) 979–992
Velez-Ortiz, D., see Vega, I.E. (4) 979–992
Vellas, B., see Bennys, K. (1) 87–97
Venneri, A., see Mirheidari, B. (2) 373–387
Verdile, G., see Gardener, S.L. (1) 193–201
Verhey, F.R.J., see Vos, S.J.B. (2) 537–547
Viaña, J.N.M., M. Bittlinger and F. Gilbert, Ethical Considerations for Deep Brain Stimulation Trials in Patients with Early-Onset Alzheimer’s Disease (2) 289–301
Vicente-Etxenausia, I., see García, B. (1) 185–192
Videla, L., see Sala, I. (3) 909–918
Vidoni, E.D., see Morris, J.K. (4) 1129–1135
Vidorreta, M., see de Eulate, R.G. (2) 585–595
Villemagne, V.L., see Lim, Y.Y. (4) 1293–1302
Vipin, A., see Tan, Y.J. (2) 413–423
Visser, P.J., see Vos, S.J.B. (2) 537–547
von Hoff, F., see Busse, M. (4) 1303–1313
Vorobyov, V., see Gordon, R. (3) 711–724
Vos, S.J.B., M.P.J. van Boxtel, O.J.G. Schiepers, K. Deckers, M. de Vugt, I. Carrière, J.-F. Dartigues, K. Peres, S. Artero, K. Ritchie, L. Galluzzo, E. Scafato, G.B. Frisoni, M. Huisman, H.C. Comijs, S.F. Sacuiu, I. Skoog, K. Irving, C.A. O’Donnell, F.R.J. Verhey, P.J. Visser and S. Köhler, Modifiable Risk Factors for Prevention of Dementia in Midlife, Late Life and the Oldest-Old: Validation of the LIBRA Index (2) 537–547
Vriend, A.E., see Mahinrad, S. (1) 275–283
Wagenpfeil, S., see Robb, C. (1) 69–78
Wagner, M., see Wolfsgruber, S. (3) 939–950
Walhovd, K.B., see Sala-Llonch, R. (3) 829–840
Walker, R.L., see Dublin, S. (2) 435–448
Walker, T., see Mirheidari, B. (2) 373–387
Walker, Z., see Sadiq, D. (2) 463–470
Wang, H., see Li, Y. (4) 1175–1187
Wang, L., see Siedlak, S.L. (4) 1027–1033
Wang, S., see Tian, S. (4) 1163–1173
Wang, T., Y. Wu, Y. Sun, L. Zhai and D. Zhang, A Prospective Study on the Association between Uric Acid and Cognitive Function among Middle-Aged and Older Chinese (1) 79–86
Wang, X., see Siedlak, S.L. (4) 1027–1033
Wang, Y.-J., see Jin, W.-S. (3) 919–925
Wang, Y.-R., see Jin, W.-S. (3) 919–925
Watne, L.O., see Sala-Llonch, R. (3) 829–840
Weerasekara, S., see Maezawa, I. (2) 559–574
Weinborn, M., see Gardener, S.L. (1) 193–201
Weiner, M.W., see Deters, K.D. (4) 1245–1254
West, J.D., see Deters, K.D. (4) 1245–1254
Whitfield, T., see Sadiq, D. (2) 463–470
Wikkelsø, C., see Edsbagge, M. (3) 821–828
Wilkins, H.M., see Morris, J.K. (4) 1129–1135
Williams, S.M., P. Schulz, T.L. Rosenberry, R.J. Caselli and M.R. Sierks, Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimer’s Disease (1) 23–35
Williamson, R., see Lim, Y.Y. (4) 1293–1302
Wilson, G.D., see Yilmaz, A. (2) 355–359
Wiltfang, J., see Wolfsgruber, S. (3) 939–950
Winblad, B., see Cermakova, P. (4) 1265–1272
Wolfsgruber, S., A. Polcher, A. Koppara, L. Kleineidam, L. Frölich, O. Peters, M. Hüll, E. Rüther, J. Wiltfang, W. Maier, J. Kornhuber, P. Lewczuk, F. Jessen and M. Wagner, Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment (3) 939–950
Wu, Y., see Wang, T. (1) 79–86
Wygant, C.M., see Vega, I.E. (4) 979–992
Wyller, T.B., see Sala-Llonch, R. (3) 829–840
Xie, B., Z. Liu, W. Liu, L. Jiang, R. Zhang, D. Cui, Q. Zhang and S. Xu, DNA Methylation and Tag SNPs of the BDNF Gene in Conversion of Amnestic Mild Cognitive Impairment into Alzheimer’s Disease: A Cross-Sectional Cohort Study (1) 263–274
Xie, F., see Siedlak, S.L. (4) 1027–1033
Xie, X.S., see Maezawa, I. (2) 559–574
Xu, M., see Liu, G. (4) 1121–1128
Xu, S., see Xie, B. (1) 263–274
Yakushev, I., see Pasquini, L. (3) 763–773
Yamasaki, R., see Nakamura, N. (4) 1151–1161
Yamazaki, C., T. Tamaoki, A. Nunomura, K. Tamai, K. Yasuda and N. Motohashi, Plasma Amyloid-b and Alzheimer’s Disease-Related Changes in Late-Life Depression (2) 349–354
Yamazaki, K., see Yoshino, Y. (3) 687–694
Yanagihara, Y.T., see Nakamura, N. (4) 1151–1161
Yang, X.-y., see Liu, G. (4) 1121–1128
Yang, Y., G.M. Halliday, J.R. Hodges and R.H. Tan, von Economo Neuron Density and Thalamus Volumes in Behavioral Deficits in Frontotemporal Dementia Cases with and without a C9ORF72 Repeat Expansion (3) 701–709
Yao, X.-Q., see Jin, W.-S. (3) 919–925
Yasuda, K., see Yamazaki, C. (2) 349–354
Yilmaz, A., T. Geddes, B. Han, R.O. Bahado-Singh, G.D. Wilson, K. Imam, M. Maddens and S.F. Graham, Diagnostic Biomarkers of Alzheimer’s Disease as Identified in Saliva using 1H NMR-Based Metabolomics (2) 355–359
Yin, X., see Reddy, P.H. (1) 147–162
Yoon, S.-Y., see An, H. (1) 253–261
Yoshida, T., see Yoshino, Y. (3) 687–694
Yoshino, Y., K. Yamazaki, Y. Ozaki, T. Sao, T. Yoshida, T. Mori, Y. Mori, S. Ochi, J.-I. Iga and S.-I. Ueno, INPP5D mRNA Expression and Cognitive Decline in Japanese Alzheimer’s Disease Subjects (3) 687–694
Youn, Y.C., see Moon, B. (4) 1255–1264
Yu, H., see Li, Y. (4) 1175–1187
Yu, J.-T., see Yuan, X.-Z. (2) 303–322
Yu, J.-T., see Zhu, J.-B. (3) 631–659
Yu, O., see Dublin, S. (2) 435–448
Yuan, X.-Z., S. Sun, C.-C. Tan, J.-T. Yu and L. Tan, The Role of ADAM10 in Alzheimer’s Disease (2) 303–322
Zakzanis, K.K., see Berezuk, C. (2) 425–434
Zamarian, L., see Pertl, M.-T. (4) 1077–1087
Zeng, F., see Jin, W.-S. (3) 919–925
Zeng, L., see Tan, Y.J. (2) 413–423
Zetterberg, H., see Deters, K.D. (4) 1245–1254
Zetterberg, H., see Edsbagge, M. (3) 821–828
Zetterberg, H., see Sala-Llonch, R. (3) 829–840
Zhai, L., see Wang, T. (1) 79–86
Zhang, D., see Wang, T. (1) 79–86
Zhang, M., see Maezawa, I. (2) 559–574
Zhang, Q., see Xie, B. (1) 263–274
Zhang, R., see Xie, B. (1) 263–274
Zhang, T., see Jin, W.-S. (3) 919–925
Zhang, Z., see Gu, L. (4) 1283–1292
Zhang, Z., see Sun, J. (3) 597–612
Zhao, B., see Jiang, C. (1) 1–15
Zhou, H., see Sun, J. (3) 597–612
Zhou, H.-D., see Jin, W.-S. (3) 919–925
Zhou, J., see Tan, Y.J. (2) 413–423
Zhu, C., see Jin, W.-S. (3) 919–925
Zhu, J.-B., C.-C. Tan, L. Tan and J.-T. Yu, State of Play in Alzheimer’s Disease Genetics (3) 631–659
Zilka, N., see Skrabana, R. (4) 1017–1025
Zisapel, N., see Pinner, E. (4) 1137–1149
Zou, B., see Maezawa, I. (2) 559–574
Zubieta, J.L., see de Eulate, R.G. (2) 585–595